SpiroChem – PeptiFinder Strategic Partnership Materials
SpiroChem and PeptiFinder Partner to Build an Integrated Discovery Engine for Peptide and Macrocycle Therapeutics
Basel, Switzerland; Montreal, Canada; and Boston, MA, USA - March 23, 2026 - SpiroChem AG and PeptiFinder Biotech today announced a strategic partnership to establish an integrated discovery engine for peptide and macrocycle drug discovery, combining advanced hit generation with proprietary medicinal chemistry and molecular optimization to accelerate the development of drug candidates against difficult-to-drug targets.
The collaboration brings together PeptiFinder’s mRNA display platform for hit generation and SpiroChem’s proprietary chemistry platform for hit validation, hit-to-lead, and lead optimization. Together, the two companies offer a seamless discovery workflow from initial binder identification through to optimized lead candidates.
This partnership is designed as a platform-driven discovery model, integrating two highly complementary modules into a single, coherent engine. PeptiFinder enables the exploration of ultra-large peptide libraries using mRNA display to identify high-affinity binders against challenging targets. SpiroChem contributes a proprietary medicinal chemistry platform combining macrocycle design, advanced peptidomimetic chemistry, and physicochemical and pharmacological optimization to transform peptide hits into drug-like molecules.
By bridging hit discovery and molecular optimization within a unified framework, the partnership addresses a key limitation in early discovery: fragmentation between upstream screening and downstream medicinal chemistry.
“Combining PeptiFinder’s mRNA display platform with SpiroChem’s proprietary chemistry capabilities creates a highly complementary and differentiated offering for early discovery,” said Thomas Fessard, CEO of SpiroChem. “This is a true platform play: a hit-generation module seamlessly connected to a medicinal chemistry and optimization engine. Our peptidomimetic toolbox enables systematic de-peptidization strategies to remove peptide-intrinsic liabilities early, transforming binders into developable molecules. We believe this integrated approach will resonate strongly with partners seeking faster and more efficient paths from target to lead.”
“Partnering with SpiroChem extends the value of our mRNA display platform beyond hit identification,” said Yongjin Gong, CBO and Co-Founder of PeptiFinder. “Together, we provide a more complete and efficient solution—from high-affinity binder discovery to optimized therapeutic candidates—helping our partners accelerate early discovery programs.”
The partnership will also be supported by coordinated commercial and scientific activities, including joint business development, co-marketing initiatives, and co-branded engagements. Leveraging a transatlantic footprint across Boston, Montreal, and Switzerland, the collaboration is positioned to support biopharma partners across the United States, Europe, and Japan.
Under the collaboration, clients benefit from an integrated workflow including:
Hit generation via mRNA display
Hit validation and screening follow-up
Medicinal chemistry optimization and SAR development
Macrocycle and peptidomimetic design
Lead identification and progression toward preclinical candidate selection
The companies expect this partnership to serve as a foundation for future expansion of their integrated discovery capabilities across additional modalities.
About PeptiFinder
PeptiFinder Biotech is a biotechnology company specializing in mRNA display-based hit generation for peptide discovery. Its platform enables the screening of ultra-large peptide libraries to identify high-affinity binders against a wide range of biological targets, including those traditionally considered difficult to drug. Additionally, through the incorporation of unnatural amino acids into macrocyclic peptide libraries, PeptiFinder’s mRNA display platform can generate peptide hits with enhanced physicochemical properties and optimized pharmacokinetic profiles.
By combining advanced display technologies with robust selection workflows, PeptiFinder delivers high-quality peptide hits with strong binding affinity, specificity, and improved overall properties. Based in the Boston area, PeptiFinder partners with pharmaceutical and biotechnology companies to accelerate early-stage drug discovery programs.
Executive Summary
SpiroChem and PeptiFinder have established a strategic partnership built around a two-platform discovery model for peptide and macrocycle therapeutics.
The collaboration integrates:
- PeptiFinder’s mRNA display platform for the identification of peptide binders from ultra-large libraries against challenging targets
- SpiroChem’s proprietary chemistry platform for macrocycle design, medicinal chemistry optimization, and physicochemical property enhancement
Together, these complementary capabilities form an integrated discovery engine designed to accelerate the transition from target engagement to optimized lead candidates.
Strategically, the partnership aims to:
- Deliver a seamless early discovery workflow for pharma and biotech partners
- Strengthen capabilities in peptide and macrocycle therapeutics
- Leverage a transatlantic presence across Boston, Montreal, Switzerland, and key global markets
- Reduce fragmentation between hit discovery and molecular optimization
LinkedIn – SpiroChem (Thomas)
We’re excited to announce a strategic partnership between SpiroChem and PeptiFinder.
Together, we are building an integrated discovery engine for peptide and macrocycle therapeutics — combining:
→ PeptiFinder’s mRNA display platform for hit generation
→ SpiroChem’s proprietary chemistry platform for hit-to-lead and lead optimization
The objective is simple:
connect hit discovery to medicinal chemistry in a seamless, platform-driven workflow.
Too often, early discovery remains fragmented. By aligning two highly complementary technologies, we aim to provide a faster and more coherent path from target to optimized lead candidates — particularly for difficult-to-drug targets.
This is not just a collaboration — it’s a platform play.
With a transatlantic footprint across Boston, Montreal, and Switzerland, we look forward to supporting partners globally.
If you’re exploring peptide or macrocycle programs, happy to discuss.
LinkedIn – PeptiFinder (Yongjin)
We’re excited to announce a strategic partnership between PeptiFinder and SpiroChem.
At PeptiFinder, we have built a powerful mRNA display platform capable of identifying high-affinity peptide binders from ultra-large libraries — including against challenging targets.
Through this partnership, we extend that capability beyond hit discovery by integrating with SpiroChem’s proprietary medicinal chemistry and optimization platforms.
Together, we are creating an integrated discovery engine that connects:
→ High-quality hit generation
→ Hit validation and screening follow-up
→ Hit-to-lead and lead optimization
The result is a more complete and efficient early discovery solution for our partners — reducing fragmentation and accelerating progress from binder identification to optimized therapeutic candidates.
